Opus Genetics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- George Magrath
- Full Time Employees
- 28
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8 Davis Drive Durham NC United States of America 27713
- IPO Date
- Jan 19, 2015
- CIK
- 0001228627
- Website
- opusgtx.com
- Similar Companies
- Business
- Opus Genetics, Inc. is a leading clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapeutic solutions for patients grappling with inherited retinal diseases and various other ophthalmic conditions. The company’s robust pipeline prominently features adeno-associated virus (AAV)-based gene therapies, including its primary candidate, OPGx-LCA5, which has demonstrated promising early visual improvements in a Phase 1/2 clinical trial for Leber congenital amaurosis type 5 and is progressing towards a pivotal adaptive Phase 3 study. Another key gene therapy, OPGx-BEST1, designed for BEST1-related inherited retinal disease, recently commenced its Phase 1/2 clinical trial. Beyond gene therapies, Opus Genetics also offers Phentolamine Ophthalmic Solution, already approved for reversing pharmacologically induced mydriasis, and is evaluating it in late-stage Phase 3 trials for presbyopia and impaired dim light vision following keratorefractive surgery. Formerly operating as Ocuphire Pharma, Inc., the entity transformed into Opus Genetics, Inc. in October 2024 through an all-stock acquisition, signifying a strategic pivot towards gene therapy development. The company continues to advance a diverse portfolio from its headquarters in Research Triangle Park, North Carolina.
Company News
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
ADAR1 Capital Management LLC Takes $7.33 Million Position in Opus Genetics, Inc. $IRD
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study